Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Everolimus is a prescription mTOR kinase inhibitor. Oncology formulations are used for selected advanced breast cancer, neuroendocrine tumors, renal cell carcinoma, and tuberous sclerosis complex conditions. Everolimus is also marketed in separate transplant formulations for prevention of organ rejection, with different dosing and monitoring requirements.
read more about everolimus ...Everolimus binds the intracellular protein FKBP-12 and forms a complex that inhibits mTOR complex 1. The mTOR pathway regulates cell growth, proliferation, metabolism, and protein synthesis and is dysregulated in several cancers and tuberous sclerosis complex. Blocking this pathway reduces downstream signaling involved in abnormal cell growth.
Oncology labeling includes selected hormone receptor-positive HER2-negative advanced breast cancer, pancreatic and gastrointestinal or lung neuroendocrine tumors, advanced renal cell carcinoma, TSC-associated renal angiomyolipoma, TSC-associated subependymal giant cell astrocytoma, and TSC-associated partial-onset seizures. The exact formulation depends on the indication.
Breast cancer, neuroendocrine tumors, renal cell carcinoma, and TSC-associated renal angiomyolipoma commonly use 10 mg once daily. TSC-associated subependymal giant cell astrocytoma starts at 4.5 mg per square meter once daily, while TSC-associated partial-onset seizures start at 5 mg per square meter once daily with blood concentration monitoring.
Serious concerns include noninfectious pneumonitis, infections, hypersensitivity, angioedema with ACE inhibitors, stomatitis, kidney failure, impaired wound healing, high blood glucose or lipids, myelosuppression, radiation recall, and fetal harm. Live vaccines are avoided during therapy, and blood counts, kidney function, glucose, lipids, and drug interactions require monitoring.
Everolimus is an mTOR kinase inhibitor used in oncology, tuberous sclerosis complex, and separate transplant formulations.
Several adult cancer indications use 10 mg once daily.
No. Current labeling treats them as different dosage forms and states that they are not combined to make the total daily dose.
Yes. Noninfectious pneumonitis is a recognized serious adverse reaction and can require dose interruption, reduction, or discontinuation.
AFINITOR (everolimus) Prescribing Information. Novartis. https://www.novartis.com/us-en/sites/novartis_us/files/afinitor.pdf. Date Accessed September 30, 2026.
DailyMed - EVEROLIMUS tablet. https://www.dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=67e62e26-448d-46ec-b5a1-00dc1b5e26c6. Date Accessed September 30, 2026.
Everolimus. MedlinePlus. https://www.medlineplus.gov/druginfo/meds/a609032.html. Date Accessed September 30, 2026.
Everolimus. National Cancer Institute. https://www.cancer.gov/about-cancer/treatment/drugs/everolimus. Date Accessed September 30, 2026.
Everolimus. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/6442177. Date Accessed September 30, 2026.